+ All Categories
Home > Documents > Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18...

Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18...

Date post: 29-Dec-2015
Category:
Upload: audrey-adams
View: 217 times
Download: 1 times
Share this document with a friend
Popular Tags:
33
ATTENTION DEFICIT HYPERACTIVITY DISORDER: OVERVIEW OF MEDICATIONS AND IMPLICATIONS Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th , 2010
Transcript
Page 1: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

ATTENTION DEFICIT HYPERACTIVITY

DISORDER:OVERVIEW OF

MEDICATIONS AND IMPLICATIONS

Sarah Schweiss, Pharm.D.

Ambulatory Care Resident

University of Minnesota & Duluth Clinic

January 18th, 2010

Page 2: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

OBJECTIVES Discuss general information and

consequences of uncontrolled ADHD. Review potential causes, the clinical

presentation, and the diagnosis of ADHD.

Outline pharmacological and non-pharmacological treatment options for ADHD.

Discuss fiction, facts, and controversies surrounding ADHD.

Briefly discuss prescription drug abuse statistics, consequences, and prevention methods.

Page 3: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

GENERAL INFORMATION

3-7% school-age childrenDiagnosis occurs as early as age 3Average age of diagnosis:_____

Up to 60% of children continue to have significant symptoms into adulthood

Males>>Females (3:1) Number of people diagnosed with

ADHD has increased by an average of 3% each year between 1997-2006 (CDC)

Page 4: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

CONSEQUENCES OF UNCONTROLLED ADHD Relationship difficulties Academic failure Social isolation Involvement with deviant peer groups Significantly greater risk of developing:

___________________________________ Low self-esteem

Page 5: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

POTENTIAL CAUSES OF ADHD Currently - no one identified cause

of ADHD Hypothesized to be caused by a

combination of environmental and genetic factors Imbalance between neurotransmitters in

the brain Norepinephrine Dopamine

Genetics Parent with ADHD = _____% chance of

developing ADHD Monozygotic twins have up to a ___%

concordance rateEnvironmental exposures

Maternal smoke or alcohol use

Page 6: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

DIAGNOSIS DSM-IV criteria

Symptoms present prior to age 6 y.o. Must involve 2 environments, e.g., school &

home Patients must meet > 6 symptoms in the

categories of impulsivity, inattention, and/or hyperactivity

Social, academic or occupational functioning is impaired

Other psychiatric illnesses are ruled out

Page 7: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

CLINICAL PRESENTATION OF ADHD:INATTENTION

Lack of attention to details Difficulty sustaining attention and

organizing Avoids tasks Difficulties listening Does not follow through on

instructions Easily distracted Forgetful in daily activities Loses things necessary for activities

Page 8: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

CLINICAL PRESENTATION OF ADHD:HYPERACTIVITY AND IMPULSIVITY

Fidgets and/or squirms Leaves seat when prohibited Runs or climbs excessively at

inappropriate times Difficulties playing quietly Often “on the go” Excessive talking Blurts out answers before completion of

question Interrupts and/or intrudes Difficulty waiting to take turns

Page 9: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

TREATMENT OPTIONS Pharmacological

PsychostimulantsNon-stimulants

Non-pharmacologicalBehavioral InterventionsCounseling/Talk TherapyFocused help with schoolworkTraining for parents

Page 10: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

NON-PHARMACOLOGICAL Behavioral Interventions

Positive reinforcementTime-outResponse CostToken economy

Parent training Family therapy Classroom interventions Contingency management

Page 11: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

OVERVIEW OF MEDICATIONS

Page 12: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

PSYCHOSTIMULANTS Methylphenidate - FDA approved for >6 yo

Immediate Release: Ritalin®, Methylin®, methylphenidate

Intermediate Acting: Ritalin SR®, Methylphenidate SR, Metadate ER, Methylin ER

Sustained Release: Metadate CD, Ritalin LA, Concerta

Dexmethylphenidate (Focalin®) – >6 yo Dextroamphetamine (Dexedrine®,Dextrostat®) >3yo Dextroamphetamine/Amphetamine (Adderall® &

Adderall XR) >3yo Desoxyephedrine/methamphetamine (Desoxyn ®)

>6yo Lisdexamfetamine (Vyvanse ®) >6yo

Page 13: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

HOW DO THEY WORK? Increase norepinephrine and dopamine

in the brain synapse May take __________ for the medication

to begin working Efficacy ranging from 70% to 96%

Page 14: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

DOSING SCHEDULE Dosing schedules differ because

duration of medications vary Immediate Release: Medication effects last

approximately 2-6 hours Usually 2-3 times/day dosing schedule

Intermediate Acting: Medication effects last approximately 6-8 hours Usually twice daily dosing

Sustained Release: Medication effects last approximately 8-12 hours Once daily dosing

Page 15: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

BENEFITS OF PSYCHOSTIMULANTS Increased attention span Decreased hyperactivity Improved impulse control Social benefits Emotional stability Improved motor skills (i.e., handwriting)

Page 16: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

ADVERSE EFFECTS

Common Side Effects Recommendation

Reduced appetite, weight loss

Stomach ache

Insomnia

Headache

Rebound Symptoms

Irritability/jitteriness

Page 17: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

ADVERSE EFFECTS Uncommon to rare

DysphoriaZombie-like stateTics or abnormal movementsHigh blood pressureHallucinations

Page 18: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

PSYCHOSTIMULANTS: PATIENT EDUCATION Empty, labeled bottle for school Keep out of sight & reach from other

children Take with food or milk Start on the weekend while parents able

to observe for any adverse effects Start once a day, then increase to twice

a day (typically breakfast & lunch) Swallow whole, DO NOT CHEW

Page 19: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

DRUG HOLIDAY Important to reassess treatment All children should be given a drug-free

trial every year Historically to allow “catch-up” growth Appropriate times for a drug holiday

WeekendsSummerNOT during holidays or start of the school

year

Page 20: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

PSYCHOSTIMULANT ABUSE POTENTIAL All psychostimulants are controlled substances Methylphenidate, dextromethylphenidate

amphetamine, dextroamphetamine, methamphetamine, and lisdexamfetamine are C-II

WARNING: POTENTIAL FOR ABUSEAmphetamines have a high potential for abuse.

Administration of amphetamines for prolonged periods of time may lead to drug dependence. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others and the drugs should be prescribed or dispensed sparingly.

Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events. - June 2009

Page 21: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

NON-STIMULANTS Straterra®

(atomoxetine) Tenex®

(guanfacine) Wellbutrin®

(bupropion) Catapres® (clonidine) Risperdal®

(risperdone) Tricyclic

antidepressants desipramine nortriptyline

Zyprexa® (olanzapine)*

Geodon® (ziprasidone)*

Haldol® (haloperidol)*

Straterra® (atomoxetine)*

* = Short-term use (1-4 months)

Page 22: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

NON-STIMULANT – STRATERRA® (ATOMOXETINE) Increases norepinephrine (NOT

DOPAMINE) in the brain synapse Side Effects

Headache InsomniaDry mouthStomach upset

Takes _____________ for max response

Page 23: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

NON-STIMULANT:TENEX® (GUANFACINE) Decreases norepinephrine

May target impulsive behavior Takes ______ to begin working Side effects

**Sedation**Dry mouthLow blood pressure – WARNING: rebound

hypertension if abruptly stoppedSlow heart beatDizziness

Page 24: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

CONTROVERSIES SURROUNDING ADHD

Growth suppression w/ stimulant use ADHD = 2-fold greater risk of substance

abuse Cancer Helps student get straight A’s Decreases seizure threshold Causes Tourette syndrome Herbal/Alternative medications

Pedi-ActivePycnogenol

Page 25: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

ADHD EDUCATIONAL WEBSITES American Academy of Child and

Adolescent Psychiatry – www.aacap.org Attention Deficit Disorder Association –

http://www.add.org/ Parents Helping Parents: Family

Resource Center for Children with Special Needs – http://www.php.com

National Resource Center on ADHD – http://www.help4adhd.org/

Page 26: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

PRESCRIPTION DRUG ABUSE IN TEENS The nonmedical use of prescription drugs

ranks ___ among the most abused class of drugs by adolescents

_________ of teens do not see a great risk in trying prescription pain relievers without a prescription

Rationale behind abusePrescription medications are “safer” Readily availableLess shame attached to using themFewer side effectsLess consequences if parents catch them

Page 27: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

MOST COMMONLY ABUSED PRESCRIPTION MEDICATIONS1. Painkillers – Prescribed to treat pain

codeine, oxycodone, fentanyl, morphine Brand Names: OxyContin, Percocet,

Vicodin/Lortab, Duragesic

2. Depressants – Mainly prescribed to treat anxiety and sleep disorders

Benzodiazepines, barbituates, etc. Brand Names: Klonopin, Soma, Valium,

Xanax

3. Stimulants – Mainly prescribed to treat ADHD

Amphetamines, methylphenidate, etc. Brand Names: Adderall, Concerta, Dexedrine,

Ritalin

Page 28: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

SIGNS AND SYMPTOMS OF PRESCRIPTION DRUG ABUSE Constricted pupils Slurred speech Flushed skin Sweating Lack of appetite Mood swings Personality changes Excessive energy Drowsiness Forgetfulness

Acting secretive Losing interest in

personal appearance

Borrowing $/having extra cash

Skipping classes Poor performance in

school Prescription and

over-the-counter medication signs

Page 29: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.
Page 30: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

STRATEGIES FOR PREVENTION Open discussion Parent-focused information and training

Monitor teenagers internet use Watch for suspicious behaviorsKeep track of prescription and over-the-

counter medications Education within the school system Pharmacy involvement

Medication guides Age restrictions for purchasing frequently

abused over-the-counter medications Proper training of medical personnel

Page 31: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

ACKNOWLEDGEMENTS

Mark E. Schneiderhan, Pharm.D., BCPPAssociate ProfessorUniversity of Minnesota - DuluthDepartment of Pharmacy Practice and Pharmaceutical Sciences

Page 32: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

REFERENCES1. DiPiro, J. T., et al. Pharmacotherapy : a pathophysiologic

approach.  New York : McGraw-Hill, Medical Pub. Division, (2002).

2. Howard, M. M., R. M. Weiler, and J. D. Haddox. "Development and Reliability of Items Measuring the Nonmedical use of Prescription Drugs for the Youth Risk Behavior Survey: Results from an Initial Pilot Test." The Journal of school health 79.11 (2009): 554-60.

3. Salmeron, P. A. "Childhood and Adolescent Attention-Deficit Hyperactivity Disorder: Diagnosis, Clinical Practice Guidelines, and Social Implications." Journal of the American Academy of Nurse Practitioners 21.9 (2009): 488-97.

4. www.CADCA.org5. www.theantidrug.com6. Schneiderhan, Pharm.D., BCPP, Mark E. "Attention Deficit

Hyperactivity Disorder: Pharmacotherapy." University of Minnesota, Duluth, Duluth, MN. 14 Jan. 2010. Lecture.

Page 33: Sarah Schweiss, Pharm.D. Ambulatory Care Resident University of Minnesota & Duluth Clinic January 18 th, 2010.

?? QUESTIONS ??


Recommended